Matrix metalloproteinase‐7 activates heparin‐binding epidermal growth factor‐like growth factor in cutaneous squamous cell carcinoma

Background  Tumour‐specific expression of matrix metalloproteinase (MMP)‐7 has been noted in cutaneous squamous cell carcinomas (SCCs) in patients with recessive dystrophic epidermolysis bullosa (RDEB).

[1]  Jiahuai Han,et al.  p38 Mitogen-activated protein kinase pathway suppresses cell survival by inducing dephosphorylation of mitogen-activated protein/extracellular signal-regulated kinase kinase1,2. , 2020, Cancer research.

[2]  H. Modjtahedi,et al.  Epidermal growth factor receptor inhibitors in cancer treatment: advances, challenges and opportunities. , 2009, Anti-cancer drugs.

[3]  C. Has,et al.  Forty‐two novel COL7A1 mutations and the role of a frequent single nucleotide polymorphism in the MMP1 promoter in modulation of disease severity in a large European dystrophic epidermolysis bullosa cohort , 2009, The British journal of dermatology.

[4]  S. Nadler,et al.  MMP7 Shedding of Syndecan-1 Facilitates Re-Epithelialization by Affecting α2β1 Integrin Activation , 2009, PloS one.

[5]  Leena Latonen,et al.  CCHCR1 Is Up-Regulated in Skin Cancer and Associated with EGFR Expression , 2009, PloS one.

[6]  J. McGrath,et al.  Increased invasive behaviour in cutaneous squamous cell carcinoma with loss of basement-membrane type VII collagen , 2009, Journal of Cell Science.

[7]  P. Itin,et al.  Cetuximab Therapy of Metastasizing Cutaneous Squamous Cell Carcinoma in a Patient with Severe Recessive Dystrophic Epidermolysis Bullosa , 2009, Dermatology.

[8]  C. Suchindran,et al.  Epidermolysis bullosa and the risk of life-threatening cancers: the National EB Registry experience, 1986-2006. , 2009, Journal of the American Academy of Dermatology.

[9]  M. Koch,et al.  Supramolecular Interactions in the Dermo-epidermal Junction Zone , 2008, Journal of Biological Chemistry.

[10]  M. Lacouture,et al.  Risk of High-Grade Skin Rash in Cancer Patients Treated with Cetuximab – an Antibody against Epidermal Growth Factor Receptor: Systemic Review and Meta-Analysis , 2008, Oncology.

[11]  E. Bauer,et al.  The classification of inherited epidermolysis bullosa (EB): Report of the Third International Consensus Meeting on Diagnosis and Classification of EB. , 2008, Journal of the American Academy of Dermatology.

[12]  H. Shimizu,et al.  Transformation‐specific matrix metalloproteinases (MMP)‐7 and MMP‐13 are expressed by tumour cells in epidermolysis bullosa‐associated squamous cell carcinomas , 2008, The British journal of dermatology.

[13]  C. Bodemer,et al.  A frequent functional SNP in the MMP1 promoter is associated with higher disease severity in recessive dystrophic epidermolysis bullosa , 2008, Human mutation.

[14]  J. Uitto,et al.  Recessive dystrophic epidermolysis bullosa-associated squamous-cell carcinoma: an enigmatic entity with complex pathogenesis. , 2007, The Journal of investigative dermatology.

[15]  James T. Elder,et al.  Differential ErbB1 signaling in squamous cell versus basal cell carcinoma of the skin. , 2007, The American journal of pathology.

[16]  C. Bodemer,et al.  Epigallocatechin gallate's protective effect against MMP7 in recessive dystrophic epidermolysis bullosa patients. , 2007, The Journal of investigative dermatology.

[17]  J. Scoazec,et al.  Matrilysin 1 influences colon carcinoma cell migration by cleavage of the laminin-5 beta3 chain. , 2006, Cancer research.

[18]  B. Baldursson,et al.  Expression of matrix metalloproteinase (MMP)‐7 and MMP‐13 and loss of MMP‐19 and p16 are associated with malignant progression in chronic wounds , 2005, The British journal of dermatology.

[19]  J. Arbiser,et al.  Involvement of p53 and p16 tumor suppressor genes in recessive dystrophic epidermolysis bullosa-associated squamous cell carcinoma. , 2004, The Journal of investigative dermatology.

[20]  J. McGrath,et al.  Expression and glycosylation of MUC1 in epidermolysis bullosa‐associated and sporadic cutaneous squamous cell carcinomas , 2004, The British journal of dermatology.

[21]  J. McGrath,et al.  Reduced expression of insulin-like growth factor-binding protein-3 (IGFBP-3) in Squamous cell carcinoma complicating recessive dystrophic epidermolysis bullosa. , 2004, The Journal of investigative dermatology.

[22]  J. Eriksson,et al.  Tissue inhibitor of metalloproteinases-3 induces apoptosis in melanoma cells by stabilization of death receptors , 2003, Oncogene.

[23]  E. Kerkelä,et al.  Matrix metalloproteinases in tumor progression: focus on basal and squamous cell skin cancer , 2003, Experimental dermatology.

[24]  L. Bruckner-Tuderman,et al.  Dystrophic epidermolysis bullosa complicated by cutaneous squamous cell carcinoma and pulmonary and renal amyloidosis , 2003, Clinical and experimental dermatology.

[25]  R. Mallipeddi,et al.  Epidermolysis bullosa and cancer , 2002, Clinical and experimental dermatology.

[26]  V. Kähäri,et al.  Matrix metalloproteinases in cancer: Prognostic markers and therapeutic targets , 2002, International journal of cancer.

[27]  I. Stamenkovic,et al.  CD44 anchors the assembly of matrilysin/MMP-7 with heparin-binding epidermal growth factor precursor and ErbB4 and regulates female reproductive organ remodeling. , 2002, Genes & development.

[28]  N. Sepp,et al.  Squamous cell carcinoma in junctional and dystrophic epidermolysis bullosa. , 2001, Acta dermato-venereologica.

[29]  K. Bennett,et al.  Colocalization of basic fibroblast growth factor and CD44 isoforms containing the variably spliced exon v3 (CD44v3) in normal skin and in epidermal skin cancers , 1999, The British journal of dermatology.

[30]  L. Bruckner-Tuderman,et al.  Hereditary skin diseases of anchoring fibrils. , 1999, Journal of dermatological science.

[31]  J. Kononen,et al.  Tissue microarrays for high-throughput molecular profiling of tumor specimens , 1998, Nature Medicine.

[32]  J. Folkman,et al.  Basic Fibroblast Growth Factor: A Missing Link between Collagen VII, Increased Collagenase, and Squamous Cell Carcinoma in Recessive Dystrophic Epidermolysis Bullosa , 1998, Molecular medicine.

[33]  V. Kähäri,et al.  Human collagenase-3 is expressed in malignant squamous epithelium of the skin. , 1997, The Journal of investigative dermatology.

[34]  W. Parks,et al.  Matrix metalloproteinase matrilysin is constitutively expressed in adult human exocrine epithelium. , 1995, The Journal of investigative dermatology.

[35]  K. Bennett,et al.  Regulation of growth and dissemination of a human lymphoma by CD44 splice variants. , 1995, Journal of cell science.

[36]  K. Imai,et al.  Matrix Metalloproteinase 7 (Matrilysin) from Human Rectal Carcinoma Cells , 1995, The Journal of Biological Chemistry.

[37]  I. Stamenkovic,et al.  CD44 isoforms containing exon V3 are responsible for the presentation of heparin-binding growth factor , 1995, The Journal of cell biology.

[38]  J. Uitto,et al.  Molecular basis of the dystrophic and junctional forms of epidermolysis bullosa: mutations in the type VII collagen and kalinin (laminin 5) genes. , 1994, The Journal of investigative dermatology.

[39]  J. McGrath,et al.  Structural variations in anchoring fibrils in dystrophic epidermolysis bullosa: correlation with type VII collagen expression. , 1993, The Journal of investigative dermatology.

[40]  J. Bell,et al.  Genomic structure of DNA encoding the lymphocyte homing receptor CD44 reveals at least 12 alternatively spliced exons. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[41]  H. Joensuu,et al.  UT-MUC-1, a new mucoepidermoid carcinoma cell line, and its radiosensitivity. , 1992, Archives of otolaryngology--head & neck surgery.

[42]  J. McGrath,et al.  Epidermolysis bullosa complicated by squamous cell carcinoma: report of 10 cases , 1992, Journal of cutaneous pathology.

[43]  L. Bruckner-Tuderman,et al.  Anchoring fibrils and type VII collagen are absent from skin in severe recessive dystrophic epidermolysis bullosa. , 1989, The Journal of investigative dermatology.

[44]  R. Warnke,et al.  Suppression of endogenous avidin-binding activity in tissues and its relevance to biotin-avidin detection systems. , 1981, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[45]  A. A. Clairmont,et al.  Marjolin's ulcer. , 1979, Pennsylvania medicine.

[46]  J. Q. Rosso,et al.  Epidermolysis bullosa and the risk of life-threatening cancers: The National EB Registry experience, 1986-2006 , 2010 .

[47]  J. Heino,et al.  Collagenase-3 (MMP-13) enhances remodeling of three-dimensional collagen and promotes survival of human skin fibroblasts. , 2007, The Journal of investigative dermatology.

[48]  M. Mareel,et al.  Release of an invasion promoter E-cadherin fragment by matrilysin and stromelysin-1. , 2001, Journal of cell science.

[49]  P. Kincade,et al.  CD44 and its interaction with extracellular matrix. , 1993, Advances in immunology.